Hypertriglyceridaemia (HTG) is an important risk factor for metabolic fatty liver disease – an umbrella term for multiple common chronic liver diseases for which triglyceride-lowering agents are starting to show encouraging benefits. Professor Robert Rosenson (Icahn School of Medicine at Mount Sinai, New York, USA) examines the evidence linking triglycerides to fatty liver disease and current and potential approaches to treatment.
Redemplo (plozasiran) receives US approval for FCS
The US Food and Drug Administration (FDA) has approved Redemplo (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronaemia syndrome (FCS). The apoC3 siRNA will be available in the USA before the end of the year.
ANGPTL4: An important regulator of cholesterol and triglyceride metabolism
As the first agents targeting ANGPTL4 progress through clinical trials investigating their potential to lower triglyceride levels, Professor Sander Kersten (Cornell University, New York, USA) considers the role of ANGPTL4 in lipid metabolism, its mechanism of action, and latest data supporting the growing interest in ANGPTL4 inhibition as an opportunity for reducing cardiovascular risk.
APOC3 gene-silencing agents predicted to reduce heart disease risk by 25%
Novel APOC3 gene-silencing agents currently in development could reduce coronary heart disease (CHD) risk by approximately 25% during a 5-year outcomes trial. This conclusion is based on results from a polygenic score (PGS)-based model to investigate if the degree of triglyceride rich lipoprotein (TRL)/remnant reduction seen with APOC3 gene-silencing would lead to a meaningful reduction […]
Growing support for benefits of remnant reduction
Reducing remnant cholesterol (RC) levels by at least 50% in individuals with levels >1 mmol/L (39 mg/dL) may have substantial benefits in reducing their risk of atherosclerotic cardiovascular disease (ASCVD).
Tryngolza (olezarsen) receives EU approval for FCS treatment
The European Commission has approved Tryngolza (olezarsen) for use in the European Union (EU) as an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS). The approval is based on positive data from the Phase 3 Balance study, in which olezarsen 80 mg significantly reduced fasting TG levels at six months, and was associated with a reduction in acute pancreatitis at week 53.
